Nature Communications (Jun 2018)
Patient derived organoids to model rare prostate cancer phenotypes
- Loredana Puca,
- Rohan Bareja,
- Davide Prandi,
- Reid Shaw,
- Matteo Benelli,
- Wouter R. Karthaus,
- Judy Hess,
- Michael Sigouros,
- Adam Donoghue,
- Myriam Kossai,
- Dong Gao,
- Joanna Cyrta,
- Verena Sailer,
- Aram Vosoughi,
- Chantal Pauli,
- Yelena Churakova,
- Cynthia Cheung,
- Lesa Dayal Deonarine,
- Terra J. McNary,
- Rachele Rosati,
- Scott T. Tagawa,
- David M. Nanus,
- Juan Miguel Mosquera,
- Charles L. Sawyers,
- Yu Chen,
- Giorgio Inghirami,
- Rema A. Rao,
- Carla Grandori,
- Olivier Elemento,
- Andrea Sboner,
- Francesca Demichelis,
- Mark A. Rubin,
- Himisha Beltran
Affiliations
- Loredana Puca
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- Rohan Bareja
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Davide Prandi
- Center for Integrative Biology, University of Trento
- Reid Shaw
- Cure First and SEngine Precision Medicine
- Matteo Benelli
- Center for Integrative Biology, University of Trento
- Wouter R. Karthaus
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Judy Hess
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- Michael Sigouros
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- Adam Donoghue
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- Myriam Kossai
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Dong Gao
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Joanna Cyrta
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Verena Sailer
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Aram Vosoughi
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Chantal Pauli
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Yelena Churakova
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Cynthia Cheung
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Lesa Dayal Deonarine
- Meyer Cancer Center, Weill Cornell Medicine
- Terra J. McNary
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Rachele Rosati
- Cure First and SEngine Precision Medicine
- Scott T. Tagawa
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- David M. Nanus
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- Juan Miguel Mosquera
- Meyer Cancer Center, Weill Cornell Medicine
- Charles L. Sawyers
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Yu Chen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
- Giorgio Inghirami
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine
- Rema A. Rao
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Carla Grandori
- Cure First and SEngine Precision Medicine
- Olivier Elemento
- Meyer Cancer Center, Weill Cornell Medicine
- Andrea Sboner
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Francesca Demichelis
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Mark A. Rubin
- Englander Institute for Precision Medicine,, Weill Cornell Medicine-New York Presbyterian Hospital
- Himisha Beltran
- Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medicine
- DOI
- https://doi.org/10.1038/s41467-018-04495-z
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 10
Abstract
There are few available models to study neuroendocrine prostate cancer. Here they develop and characterize patient derived organoids from metastatic lesions, use these models to show the role of EZH2 in driving neuroendocrine phenotype, and perform high throughput organoid screening to identify therapeutic drug combinations.
